Sector News

Bristol-Myers’ Doug Manion becomes new chief at I-O biotech Kleo

June 12, 2017
Life sciences

GlaxoSmithKline, Dupont and Bristol-Myers Squibb vet Douglas Manion, M.D., FRCP(C), has become the new CEO of Kleo Pharmaceuticals.

Manion has most recently served as SVP head of specialty development at BMS and previously headed up virology at the company, as well as holding leadership positions at GSK and Dupont. He takes over from co-founder David Spiegel, M.D., Ph.D., who himself only took the top job last September.

Spiegel, a professor of chemistry and pharmacology at Yale University, now takes on the role of president at Kleo Labs.

The New Haven, Connecticut-based upstart got off its series A last fall, led by Biohaven, although more details on the financing were not shared.

Manion will now head up the biotech’s work in attempting to pioneer a new class of immunotherapies using small molecules to help a patient’s immune system fight against both cancers and infectious diseases.

“Doug brings an incredible wealth of drug discovery and development expertise and experience to the Kleo team,” said Declan Doogan, M.D., chair at Kleo. “Without a doubt, the addition of Doug will further accelerate Kleo’s place as a leader in the field of immunotherapy be it in cancer, infectious diseases or other areas of high unmet medical need.”

“I am thrilled to join Kleo Pharmaceuticals as it accelerates its quest to provide novel immunotherapies for patients with high unmet medical need,” added Manion. “The science is so compelling. I look forward to partnering with the scientists at Kleo led by David Spiegel and the rest of the team, in advancing a truly innovative approach to enlist patients’ own immune systems to fight serious disease.”

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”